The FDA has approved Rybrevant (amivantamab) in combination with chemotherapy to treat advanced, EGFR-mutant NSCLC that progressed on or after treatment with an EGFR TKI.

(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Source: Getty Images mRNA COVID-19 vaccines appear to increase PD-L1 expression across cancers, and this may explain the improved survival observed in vaccinated cancer patients receiving immune ...

Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Breast cancer is the most common cancer in women in the United States.

Colorectal cancer Overall, patients who received ramucirumab did not have longer survival. However, women and patients with left-sided primary tumors did appear to derive a benefit from ramucirumab.

Source: Getty Images “Breastfeeding is possible for the majority of patients that want to breastfeed,” said Fedro Peccatori, MD, PhD. The 7-year cumulative incidence of locoregional and/or ...